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A
mong patients presenting with chest pain at the
emergency department, the early diagnosis of acute
coronary syndromes (ACS) is a major challenge for
physicians. In 50–80% of the patients, the ECG is normal or
non-diagnostic at presentation,1 which makes early differ-
entiation from non-cardiac causes of chest pain difficult.
Serial assessment of cardiac markers results in a high
sensitivity to detect myocardial damage; however, the
absence of evidence of myocardial damage does not exclude
ACS. Therefore, novel early markers of ACS are needed. The
main cause of ACS is atherosclerotic plaque disruption with
superimposed arterial thrombus formation. Tissue factor
induced thrombin generation has a pivotal role in this
process.2 The purpose of this study was to evaluate the
diagnostic value of coagulation markers (that is, markers of
thrombin generation (prothrombin fragment 1+2 (F1+2) and
thrombin-antithrombin (TAT) complexes), soluble tissue
factor, and tissue factor pathway inhibitor (TFPI) activity)
and a fibrinolytic marker (plasminogen activator inhibitor
(PAI)) for the early identification of ACS in patients
presenting to the emergency department with chest pain
and a normal or non-diagnostic ECG.
METHODS
We performed a nested case–control study within a cohort of
patients with chest pain presenting to the emergency
department with a normal or non-diagnostic ECG within
six hours after symptoms onset. Patients were observed in
the emergency department for ( 24 hours before discharge
or hospital admission. Cardiac troponin T (cTnT) was
assessed on admission and at 12 hours after onset of
symptoms. The case group consisted of patients with ACS
with recurrent chest pain, dynamic ST segment or T wave
changes on the ECG during observation, and a negative serial
cTnT (n = 33; group 1) and of patients with ACS with at
least one positive cTnT (defined as a peak cTnT concentration
> 0.06 mg/l, n = 65; group 2). The control group (n = 62)
comprised patients without a history of cardiovascular
disease, who were considered to have chest pain of non-
cardiac origin without known or suspected thromboembolic
or infectious disease, or signs of inflammation, and who were
event free during the subsequent six months of follow up.
Venous blood samples, for the measurement of haemo-
static markers, were taken from each patient on admission to
the emergency department.
The haemostatic markers were compared between the
control group and each ACS case group by Mann-Whitney U
tests. Receiver operating characteristic (ROC) curves were
constructed for the sensitivities and specificities of the
haemostatic markers for the detection of ACS (that is, cTnT
negative or positive ACS). Additional ROC curves were
constructed specifically to detect cTnT positive ACS or cTnT
negative ACS.
RESULTS
Plasma concentrations of F1+2 and TAT complexes were
slightly higher in cTnT positive ACS patients than in controls
(median (interquartile range (IQR)) concentrations of F1+2
0.9 (0.7–1.3) v 0.8 (0.6–1.1) nmol/l, respectively; median
(IQR) concentrations of TAT 2.3 (1.0–7.6) v 1.0 (, 1.0–
4.8) ng/ml, respectively). Plasma concentrations in the cTnT
negative ACS case group were equal to those found in the
control group.
There was no difference in tissue factor plasma concentra-
tions and TFPI activity between the case groups and controls.
Among the three study groups, median soluble tissue factor
range was from 43.5–49.2 pg/ml, whereas TFPI activity
ranged between 1105–1200 U/l.
Significantly higher PAI plasma concentrations were
observed in the cTnT negative ACS patients than in controls
(median (IQR) concentrations 72.3 (44.9–131.7) ng/ml v 44.2
(30.2–83.1) ng/ml, respectively, p = 0.014). The cTnT posi-
tive ACS patients also had higher PAI concentrations than
controls; however, the difference did not reach significance
(median (IQR) concentrations 57.8 (35.5–107.2) ng/ml v 44.2
(30.2–83.1) ng/ml, respectively, p = 0.1).
Table 1 shows the diagnostic utility of the haemostatic
markers to detect patients with ACS or to identify a subgroup
with cTnT positive ACS. The cut off values presented in this
table correspond to the points of the ROC curves with the
best balance between sensitivity and specificity. As table 1
shows, the positive (PPV) and negative predictive values
(NPV) to identify patients with an ACS were comparable for
all four markers. To detect patients with a cTnT positive ACS,
F1+2 was more accurate than the other markers; however, its
PPV and NPV were only 62% and 66%, respectively.
After exclusion of cTnT positive ACS cases, only TFPI and
PAI had diagnostic value to detect cTnT negative ACS (area
under the ROC curves 0.57 (95% confidence interval (CI))
0.44 to 0.70) and 0.65 (95% CI 0.54 to 0.77), respectively). At
cut off values of TFPI . 1400 U/l and of PAI . 110 ng/ml,
the sensitivity, specificity, PPV, and NPV to identify cTnT
negative ACS were, for TFPI, 31% (95% CI 15% to 47%), 79%
(95% CI 69% to 89%), 43% (95% CI 23% to 63%), and 69%
(95% CI 58% to 80%), respectively, and for PAI, 34% (95% CI
Abbreviations: ACS, acute coronary syndromes; CI, confidence
interval; cTnT, cardiac troponin T; F1+2, prothrombin fragment 1+2; IQR,
interquartile range; NPV, negative predictive value; PAI, plasminogen
activator inhibitor; PPV, positive predictive value; ROC, receiver
operating characteristic; TAT, thrombin-antithrombin; TFPI, tissue factor
pathway inhibitor
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18% to 50%), 85% (95% CI 76% to 94%), 55% (95% CI 33% to
77%), and 72% (95% CI 62% to 82%), respectively.
DISCUSSION
Patients with cTnT positive ACS previously demonstrated
significantly increased coagulation activation than patients
with cTnT negative unstable angina.3 4 However, we could not
confirm this in our study population. We observed no
differences in plasma concentrations of coagulation markers
between patients with cTnT positive and with negative ACS.
Despite evidence of myocardial necrosis, the extent of
coagulation activation in the coronary arteries may be
insufficiently reflected by systemic plasma concentrations in
patients with a cTnT positive ACS and whose ECG does not
show characteristic changes of myocardial ischaemia.
We observed increased plasma concentrations of PAI
antigen in both ACS case groups compared with controls
but this was only significant in patients with a cTnT negative
ACS. Increased PAI plasma concentrations are associated
with common risk factors for coronary artery disease such as
hypertension and particularly diabetes.5 These two factors
were more prevalent in both case groups, in particular in the
cTnT negative ACS case group (data not shown), and this
contributed to the enhanced PAI concentrations in these
groups compared with controls.
The limited extent of coagulation activation in patients
with cTnT positive ACS was reflected by the poor diagnostic
performance of the haemostatic markers to identify these
patients. Since these patients can be identified after serial
measurement of cardiac serum markers, it remains a difficult
task to detect patients with an ACS without evidence of
myocardial damage and presenting with a non-diagnostic
ECG. In the present study, after excluding the cTnT positive
ACS cases from the analyses, only TFPI and PAI had
diagnostic value to detect patients with cTnT negative ACS
but with low PPVs of 43% and 55%, respectively. On the basis
of these markers, as many as 66–69% of the patients with
cTnT negative ACS would still not have been detected.
Thus, in our study, which is limited by relatively small
sample sizes, measurement of systemic plasma concentra-
tions of haemostatic markers did not contribute to the triage
of patients presenting with chest pain and a normal or non-
diagnostic ECG to the emergency department.
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Table 1 Utility of haemostatic markers to identify patients with an acute coronary syndrome (ACS) or specifically evolving a
cTnT positive ACS
Haemostatic marker cut off Area under the ROC curve Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Detecting ACS at large
F1+2 .1.1 nmol/l 0.53 (0.44 to 0.63) 31 (22 to 40) 80 (70 to 90) 71 (57 to 85) 42 (33 to 51)
TAT complexes .6.0 ng/ml 0.52 (0.42 to 0.61) 27 (18 to 36) 80 (70 to 90) 68 (53 to 83) 40 (31 to 49)
TFPI activity .1400 U/l 0.57 (0.48 to 0.66) 29 (20 to 38) 79 (69 to 89) 68 (54 to 82) 40 (33 to 51)
PAI .110 ng/ml 0.61 (0.52 to 0.70) 28 (19 to 37) 85 (76 to 94) 75 (61 to 89) 43 (34 to 52)
Detecting cTnT positive ACS (case group 2)
F1+2 .1.1 nmol/l 0.62 (0.53 to 0.71) 40 (28 to 52) 83 (75 to 91) 62 (47 to 77) 66 (57 to 75)
TAT complexes .6.0 ng/ml 0.59 (0.50 to 0.68) 29 (18 to 40) 79 (71 to 87) 50 (34 to 66) 61 (52 to 70)
TFPI activity .1400 U/l 0.55 (0.46 to 0.64) 28 (17 to 39) 76 (67 to 85) 44 (29 to 59) 60 (51 to 69)
PAI .95 ng/ml 0.54 (0.45 to 0.63) 29 (18 to 40) 76 (67 to 85) 45 (30 to 60) 61 (52 to 70
Data presented with 95% confidence intervals.
cTnT; cardiac troponin T; F1+2, prothrombin fragment 1+2; NPV, negative predictive value; PAI, plasminogen activator inhibitor; PPV, positive predictive value;
ROC, receiver operating characteristic; TAT, thrombin-antithrombin; TFPI, tissue factor pathway inhibitor.
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